Navigation Links
FDA Approves Redesigned Labels for Some Merck Drugs
Date:6/10/2011

SILVER SPRING, Md., June 10, 2011 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today is announcing the approval of Merck's redesigned drug container labels that include a new standardized format to improve readability and provide better information on product and strength differentiation.

(Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO)

Merck's Label Standardization Project includes the revision of 34 container labels for 16 solid oral drug products regulated by the FDA's Center for Drug Evaluation and Research (CDER). Drugs affected by the revisions include: Cozaar, Crixivan, Hyzaar, Isentress, Janumet, Januvia, Mevacor, Noroxin, Prinivil, Prinizide, Propecia, Proscar, Singulair, Zocor, and Zolinza.

"We commend Merck for their efforts," said Janet Woodcock, M.D., director of CDER. "This was no small undertaking, and we are hopeful that Merck's new standardized labels will aid in reducing pharmacy selection errors."

Merck's project included evaluating the proposed label content and layout, selecting new packaging design, and obtaining regulatory approval to implement the new packaging design. The Label Standardization Project process included:

  • a scientific approach to label design through Human Factors Engineering and Usability Studies;
  • incorporation of feedback received from the FDA and from label surveys;
  • a bundled supplement regulatory approach to ensure that labels were acceptable across CDER's eight clinical divisions.

To better access the impact of these label changes, the FDA encourages health care providers to report medication errors related to the products included in Merck's Label Standardization Project to MedWatch, the FDA's adverse event reporting program.

For more information:

MedWatch, the FDA's adverse event reporting program

http://www.fda.gov/Safety/MedWatch/default.htm

How to Report a Medication Error

http://www.fda.gov/Safety/MedWatch/HowToReport/default.htm

The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation's food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.

Media Inquiries: Morgan Liscinsky, 301-796-0379, morgan.liscinsky@fda.hhs.gov

Consumer Inquiries: 888-INFO-FDA


'/>"/>
SOURCE U.S. Food and Drug Administration
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
3. FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder
4. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
5. FDA Approves MiddleBrooks Amoxicillin PULSYS for Pharyngitis/Tonsillitis in Adolescents and Adults
6. FDA Approves XYZAL(R) (levocetirizine dihydrochloride) Oral Solution for the Relief of Seasonal and Year Round Allergies and Chronic Idiopathic Urticaria
7. UM Maryland Industrial Partnerships Program Approves 18 Collaborative Research Projects, Worth $4.4 Million, Between University Faculty, State Technology Companies
8. U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age)
9. U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older
10. FDA Approves HIFU Clinical Trial for Recurrent Prostate Cancer
11. EPA Approves XDS-CALUX(R) as Alternate Dioxin Test Method 4435
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... Mass. , February 23, 2017 - ...   ... Honoring Rare Disease Day Open to All at http://www.shire.com/RareCount   ... today announced the launch of ,Rare Count, in honor of Rare ... diseases, which equates to nearly one in 20 global citizens. It ...
(Date:2/22/2017)... , Feb. 22, 2017 IRIDEX Corporation (Nasdaq: ... release financial results for the fourth quarter and 2016 ... 2017.  The Company,s management team will host a corresponding ... p.m. ET. Investors interested in listening to ... 707-0665 for domestic callers or (703) 326-3030 for international ...
(Date:2/22/2017)... , Feb. 22, 2017 Summary ... deals and agreements entered into by the worlds leading ... Description The Global Spinal Cord Partnering Terms ... to partnering deals and agreements entered into by the ... partnering deals - Top deals by value ...
Breaking Medicine Technology:
(Date:2/22/2017)... ... February 22, 2017 , ... The Waismann Method® is providing ... who have recently fallen victim to America’s opioid epidemic. Now, opiate dependent individuals can ... they are free from the shame, stigma, and harmful labeling believed to ...
(Date:2/22/2017)... TX (PRWEB) , ... February ... ... Risk Adjustment solution leverages advanced data analytics to accurately understand each Medicare ... proper reimbursement for a given population. This new solution helps transform the ...
(Date:2/22/2017)... ... February 22, 2017 , ... ... absorption cannabidiol (CBD) serum, “NANOCALM 300” Microemulsified Hemp Extract. This premier nanoemulsified ... from the mouth into the bloodstream. Far outpacing the absorption speed ...
(Date:2/22/2017)... ... February 22, 2017 , ... Becker’s Spine Review, ... is featuring Michigan neurosurgeon Jay Jagannathan, M.D., as a “Spine Surgeon to Know.” ... of neurosurgeons in Michigan performing minimally invasive back surgery that often results in ...
(Date:2/22/2017)... ... , ... The SeniorCare Investor will host an important webinar— Seniors Housing M&A: ... 1:00 PM ET. A recording of the webinar will also be made available following ... you want to find out what really happened in the seniors housing and care ...
Breaking Medicine News(10 mins):